Daratumumab, pomalidomide, and dexamethasone in relapsed refractory multiple myeloma (RRMM): A comparison with contemporary clinical trials.

Barry Paul,Myra M. Robinson,Jordan Robinson,Ami Ndiaye,Manisha Bhutani,Peter M. Voorhees,James T. Symanowski,Reed Friend,Mauricio Pineda-Roman,Saad Z. Usmani,Shebli Atrash

Daratumumab, pomalidomide, and dexamethasone in relapsed refractory multiple myeloma (RRMM): A comparison with contemporary clinical trials.

2021

Barry Paul
Myra M. Robinson
Jordan Robinson
Ami Ndiaye
Manisha Bhutani
Peter M. Voorhees
James T. Symanowski
Reed Friend
Mauricio Pineda-Roman
Saad Z. Usmani
Shebli Atrash

e20011Background: Multiple Myeloma (MM) is an incurable malignancy of terminally differentiated plasma cells. The combination of pomalidomide/dexamethasone with either daratumumab or isatuximab is ...

Keywords:

Medicine
Internal medicine
Oncology
Pomalidomide
Daratumumab
Malignancy
relapsed refractory
Isatuximab
Dexamethasone
Clinical trial
Multiple myeloma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations